SGMT: Sagimet Biosciences Inc - Series A

SGMT新闻

• 12:35 Sagimet Biosciences: The U.S. Acne Trial Is A Replication Exercise, Not A Discovery Bet
• 12:35 After Plunging 27.9% in 4 Weeks, Here's Why the Trend Might Reverse for Sagimet Biosciences Inc. (SGMT)
• 11:15 Sagimet Biosciences 将于 2026 年 10 月 8 日至 11 日在秋季临床皮肤病学会议上公布其针对中重度寻常痤疮患者的 Denifanstat III 期 ASC40-304 开放标签延长期 52 周结果
• 11:15 Sagimet Biosciences To Present 52-Week Results From Its Phase 3 ASC40-304 Open-Label Extension Of Denifanstat In Patients With Moderate To Severe Acne Vulgaris At The 2026 Fall Clinical Dermatology Conference, October 8-11
• 10:15 HC Wainwright & Co. 重申对 Sagimet Biosciences 的“买入”评级，维持 29 美元目标价
• 10:15 HC Wainwright & Co. Reiterates Buy on Sagimet Biosciences, Maintains $29 Price Target
• 13:06 Guggenheim Maintains Buy on Sagimet Biosciences, Raises Price Target to $26
• 12:51 Oppenheimer Maintains Outperform on Sagimet Biosciences, Raises Price Target to $38
• 12:33 Citizens Maintains Market Outperform on Sagimet Biosciences, Lowers Price Target to $27
• 23:42 Sagimet Biosciences Inc. (SGMT) Discusses 52-Week Phase 3 Data and U.S. Phase 3 Plans for Denifanstat in Moderate to Severe Acne Transcript
• 18:11 Sagimet Biosciences Surges Forward With Successful Acne Clinical Data and Capital Raise
• 10:23 Sagimet Biosciences Prices $115M Offer Of 8,750,010 Shares And Warrants At $10.00/Unit
• 10:18 Sagimet Biosciences Suspends And Terminates August 14 Prospectus Supplement Regarding ATM Sales Agreement With Leerink
• 10:12 Sagimet Biosciences Announces 52-week Results From The Phase 3 ASC40-304 OLE Trial Of Denifanstat In Patients With Moderate To Severe Acne Vulgaris; Denifanstat Showed Progressive And Sustained Improvements Across All Efficacy Endpoints In The OLE...